HyTest

Delivering antibodies and antigens for the IVD industry to improve patient outcomes

Company details

Year Aquired

2018

Location

Turku, Finland

Revenue (2018)

269 mSEK

Sector

In-vitro diagnostics

Employees

110

Investment Themes

Changing Demographics

Contact

If you want to know more about HyTest please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

HyTest is a leading producer of antibodies and antigens for the in vitro diagnostic (IVD) industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care.

Through its strong market position, HyTest may have a significant impact on patient outcomes for a large group of people in developed and developing economies alike. Through its leading R&D and product suite, the company is well positioned to drive future innovation in its industry.

 

Challenge

Aging population, advances in research and technology, and the global trend of increased investments in medical care and wellness drives the need for high quality antibodies and antigens, which are key components in various laboratory assays and diagnostic kits.

 

%
Of all deaths from cardiovascular diseases are due to heart attacks or strokes
%
of chest pain cases are due to acute myocardial infarction (AMI)

 

How do we solve it?

By leveraging the latest research and state-of-theart technology, HyTest brings exceptional quality and innovation to the IVD industry. This contributes to improve health and patient outcomes globally

 

How do we improve?

Through focusing on R&D, improved technology and global expansion, the company can foster industry innovation, broaden its reach and improve health for a larger group of people.

 

Value creation

Helping the IVD industry with innovation and consistently delivering world class antibodies and antigens assists in the accuracy of IVD tests and thus patient outcomes. By broadening the company’s footprint, HyTest can increase its impact further.

Year Aquired

2018

Revenue (2018)

269 mSEK

Employees

110

Investment Themes

Changing Demographics

Sector

In-vitro diagnostics

Location

Turku, Finland

Contact

If you want to know more about HyTest please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Website

Video

SDG Alignment
SDG Wheel
SDG 3
KPI reporting
SDG 8

REVENUE (SEKm)

2018
+8%
269
2017
249
SDG 3

TESTED FOR ACUTE HEART FAILURE (HF)

Million Patients
2018
-3%
273
2017
282
SDG 3

DISEASE GROUPS COVERED

2018
20
NA
SDG 3

TESTED FOR ACUTE MYOCARDIAL INFARCTION (AMI)

Million Patients
2018
+29%
20
2019
2.2M

Learn more about HyTest

Summa Equity acquires Finnish antibody manufacturer HyTest

Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care. The investment is Summa Equity’s first in the Finnish market.   ”Antibodies…

Read the story

Summa Equity acquires Finnish antibody manufacturer HyTest

Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care. The investment is Summa Equity’s first in the Finnish market.   ”Antibodies...
Learn more